Sensitivity of Human Tumor Cells to Retinoids or Combined Treatment with Retinoids and Ionizing Radiation is not Dependent on RAR-β2 Induction

Abstract

The responsiveness of human tumor cells to retinoid treatment alone and particularly to combined treatment with irradiation is not necessarily associated with an induction of RAR-beta2 as it has been postulated so far. Thus, loss of RAR-beta induction in tumors does not seem to be a good prognostic factor for successful retinoid/radiation therapy, since RAR-beta-deficient tumors may also present strong retinoid responsiveness.

Internal Mammary Nodes in Invasive Breast Carcinoma

“…Significant controversy surrounds targeting of the IMNs with RT [1,2,4,6,8,9,12,13,18,19,24,25,[28][29][30][31][32][33]. Recent analysis of patients treated in the Danish randomized trials who received RT to the chest wall and regional lymphatics including IMNs did not show an adverse effect on cardiovascu- [14].…”

Radiation Response in Vitro of Fibroblasts from a Fanconi Anemia Patient with Marked Clinical Radiosensitivity

“…Western Blot Analysis 2 h after irradiation subconfluent control and fibroblasts irradiated with 8 Gy were detached by trypsinization, lysed in RIPA buffer (10 mM tris-HCl, pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% Triton X-100) containing protease inhibitors (2 µg/ml aprotinin, 2 µg/ml leupeptin, 5 µg/ml pepstatin, 1 mM phenylmethane sulfonyl fluoride) for 30 min on ice and subsequently centrifuged 10 min at 500× g. Samples equivalent to 20 µg of protein were separated using either 4-12% (for hMre11 and Rad51) or 3-8% (for Rad50) sodium-dodecyl-sulphate-polyacrylamide precast gels (Invitrogen, Karlsruhe, Germany) and transferred to nitrocellulose membranes according to standard procedures [7]. Equal loading and transfer were assessed by reprobing the blots with anti-β-actin antibody (Sigma A-5316) and Ponceau red (Sigma 19,976-1), respectively.…”

Radiosensitivity of Tumor Cell Lines after Pretreatment with the EGFR Tyrosine Kinase Inhibitor ZD1839 (Iressa®)

“…Recent advances in the elucidation of cell signaling networks and the development of novel agents targeting molecular pathways that affect tumor growth have led to new perspectives in cancer therapy [5,7,8,17,38]. One promising target for tumor cell sensitization is the epidermal growth factor receptor (EGFR), a member of the ErbB family of receptors.…”